MicroPort CardioFlow Medtech Corporation (for itself and on behalf of its subsidiaries) and MicroPort Scientific Corporation (for itself and on behalf of its subsidiaries and its joint ventures and associates other than the Group) entered into the 2026 International Distribution Framework Agreement I, pursuant to which the Retained MicroPort Scientific Corporation Group and its joint ventures and associates agreed to grant the Group a non-exclusive right to distribute certain products, including but not limited to, Cardiovascular Products and EP Products of the Retained MicroPort Scientific Corporation Group and its joint ventures and associates in selected overseas regions (including but not limited to Europe) and the Group agreed to procure such products from the Retained MicroPort Scientific Corporation Group and its joint ventures and associates and be responsible for their promotion and sale within selected overseas regions (including but not limited to Europe). The term is from April 8, 2026 to December 31, 2028 (both dates inclusive). The purchase price of each of the MicroPort Scientific Corporation Products shall be mutually negotiated between parties with reference to the (i) the cost of production, including raw materials, sales, and administrative expenses; (ii) transportation costs; (iii) the prevailing market gross margin for distributing similar products in the respective regions; and (iv) the prevailing market price of similar products in the respective regions, including approved tender prices, where applicable.

The Group will exert reasonable efforts to obtain at least two market quotations from Independent Third Party suppliers (if available) for products comparable to the MicroPort Scientific Corporation Products and constantly research into prevailing market conditions and practices and make reference to the pricing and terms between Group and Independent Third Parties for similar transactions to ensure that the terms for distributing the MicroPort Scientific Corporation Products are fair and reasonable, and are determined on normal commercial terms or on terms no less favorable to the Retained MicroPort Scientific Corporation Group and its joint ventures and associates than the terms available from Independent Third Parties. Regularly, the Company will review and reassess the sales prices of the MicroPort Scientific Corporation Products, making necessary adjustments in response to significant shifts in production costs, market demand, or prevailing market conditions. For each of the years ended December 31, 2024 and 2025 and two months ended February 28, 2026, the historical transaction amount of the distribution of MicroPort Scientific Corporation Products by Group was approximately nil, nil and nil, respectively.

For each of the years ended December 31, 2024 and 2025, the distribution of MicroPort Scientific Corporation Products by MicroPort CRM Group was approximately USD 3.02 million and USD 3.133 million, respectively. Pursuant to the 2026 International Distribution Framework Agreement I, it is proposed that the annual caps for the transactions contemplated thereunder for the three years ending December 31, 2028 are expected not to exceed as follows: For the year ending December 31, 2026: USD 5,000 million; 2027: USD 6,500 million; 2028: USD 7,900 million. Payment arrangements will be negotiated by the parties and stated in individual implementation agreements.

Subject to compliance with applicable laws and regulations (including but not limited to the Listing Rules) and requirements of securities regulatory authorities, the 2026 International Distribution Framework Agreement I may be renewed for a further term of no longer than three years from time to time. Upon renewal, the parties may amend the terms of such agreement based on the then prevailing circumstances. MicroPort CardioFlow Medtech Corporation (for itself and on behalf of its subsidiaries) and MicroPort Scientific Corporation (for itself and on behalf of its subsidiaries and its joint ventures and associates other than the Group) entered into the 2026 International Distribution Framework Agreement II, pursuant to which the Group agreed to grant the Retained MicroPort Scientific Corporation Group and its joint ventures and associates a non-exclusive right to distribute certain CRM Products and LAAC Products manufactured by the Group in selected overseas regions markets (including but not limited to emerging markets such as Asia Pacific, Latin America, the Middle East, Africa, and the Commonwealth of the Independent States) and the Retained MicroPort Scientific Corporation Group and its joint ventures and associates agreed to procure such products from the Group and handle their promotion and sale in such designated overseas regions.

The term is from April 8, 2026 to December 31, 2028 (both dates inclusive). The purchase price of each of the Group Products shall be mutually negotiated between parties with reference to the (i) the cost of production, including raw materials, sales, and administrative expenses; (ii) transportation costs; (iii) the prevailing market gross margin for distributing similar products in the respective regions; and (iv) the prevailing market price of similar products in the respective regions, including approved tender prices, where applicable. The Finance Department will regularly review and re-assess the sales prices of the Group Products and delivery method semiannually and adjust if there are any significant changes in the production cost, demands or the prevailing market prices.

It is expected that the prices of the Group Products to be charged by the Group to the Retained MicroPort Scientific Corporation Group and its joint ventures and associates shall be no less favorable to the Group than prices charged to Independent Third Party distributors, if any, for the same products under similar conditions in the relevant regions, and ensure that the relevant agreements are fair and reasonable, and on normal commercial terms. For each of the years ended December 31, 2024 and 2025 and two months ended February 28, 2026, the historical transaction amount of the 2026 International Distribution Framework Agreement II was approximately nil, USD 17,000 and USD 357,000, respectively.